Circulating tumor cells (CTCs) are a population of tumor-derived cells that detach from the primary tumor and initiate metastasis. However, the mechanisms of this process are still unknown. This phenomenon renders CTCs as a valuable resource for prognosis and diagnosis of cancer. The involvement of stemness transcription factors and markers, such as NANOG, OCT3/4, CD34, NESTIN, and SOX2, in metastasis initiation has been studied recently because their abnormally elevated expression in cancer cells may be highly important in understanding tumor initiation. This study analyzed the genetic profiles of the above genes in CTCs derived from patients with different types of cancer. Blood samples were randomly collected from 71 cancer patients with various cancer types. CTCs were isolated using enrichment protocols and RNA was extracted. RT-qPCR was performed in triplicate using ACTB as the reference gene. The statistical analysis was performed among the ΔCts of the samples using parametric and non-parametric methods. The molecular analysis revealed that the expression of each gene was different than the others. When each type of cancer was analyzed separately, the gene expression profile was not always the same. It is noteworthy that, in all cases, the gene expression of NESTIN differed from that of transcription factors. According to the above data, gene expression profiles might be used as a potential biomarker or constitute a gene signature.
quently spreading to other organs where they can initiate tumor metastasis in the new microenvironment. Nevertheless, the mechanisms of detachment from the tumor site and re-establishment at a different site are still unknown.
CTCs were first reported by Thomas Ashworth in 1869 [1] . Since then, CTCs have been the focus of many researchers, because they have proved to have both prognostic and diagnostic value. The existence of CTCs has been reported in most solid cancers, and their use as a diagnostic resource is well established [2] .
Another cell subpopulation with EMT properties is cancer stem cells (CSCs).
These cells have been proposed to initiate cancer and propagate metastasis, and are capable of self-renewal and regenerating the tumor [3] . Many studies have been performed to identify the gene signatures of CSCs. However, there are no clear data on this issue. NANOG, OCT3/4, SOX2, NESTIN, and CD34 constitute a well-characterized gene group for stem cells [4] . Yu et al. have proven that NANOG, SOX2 and OCT3/4 induce pluripotency to somatic cells that do not normally express these factors [5] . Moreover, NANOG, SOX2 and OCT3/4 are overexpressed in the majority of cancer types [6] [7] . On the other hand, NESTIN is a stemness marker of both neurological tumors and tumors of epithelial and mesenchymal origin [8] , and CD34 is a common marker or progenitor cell [9] .
Pardal et al., reviewing the principles of stem-cell biology to cancer, stated that "several signalling pathways that regulate normal stem-cell self-renewal cause neoplastic proliferation when dysregulated by mutations" [10] . Therefore, the study of stemness markers that have been correlated both to stem-cells and to cancer-derived cells could possibly explain the mechanisms of self-renewal in cancer. Therefore, the present study aimed to identify the gene expression of the above stemness transcription factors and markers in CTCs derived from various types of cancer.
Results
The statistical analysis among all cancer types revealed that the expression of each gene was significantly different when all samples were included (p = 0.0001). In terms of the gene expression rates, higher expression was observed for OCT3/4, followed by NANOG and SOX2. CD34 was expressed at lower levels, while NESTIN exhibited the lowest gene expression (Figure 1 ). When the analysis was performed in each type of cancer, the data were not the same. In In melanoma and glioblastoma CTCs, except for the former, there were also differences between OCT3/4 and SOX2 (p = 0.04/p = 0.01). In cases of primary tumors with an unknown origin, the analysis revealed differences in the gene expression of all markers except for NANOG-OCT3/4 (p = 0.06). When the analysis was performed in breast CTCs, according to the state of the disease, there were no significant differences. Figure 2 represents the above data.
Regarding the gene expression among the different types of cancer, NANOG's expression was higher in ovarian, melanoma, sarcoma and multiple myeloma cancer and lower in breast, colon and prostate carcinoma. The lower expression was observed in SCC and in unknown origin of primary tumor cases. In OCT3/ 4, the higher expression was observed for sarcoma, melanoma and multiple myeloma while the gene expression in the other types was lower with no significant differences among them. Regarding CD34 gene expression, the higher expression was for sarcoma samples followed by caner of unknown origin and colon. The SCC cases had the lower expression, however with no great difference. In NESTIN, the lower expression was for SCC and increasing followed glioblastoma, multiple myeloma, prostate, breast, unknown origin of primary tumor, melanoma, colon and ovarian, while sarcoma demonstrated the higher gene expression levels. Finally, in SOX2 gene, the higher expression observed in ovarian cancer, followed in decreasing rate by myeloma and sarcoma. Breast, colon, prostate and glioblastoma samples exhibited similar gene expression levels, higher that SCC and unknown origin tumor which had the lower SOX2 Figure 2 . Gene expression differences among NANOG, OCT3/4, CD34, NESTIN, and SOX2 in various cancer types. qPCR data of all samples categorized per cancer type are shown. Symbols indicate statistically significant differences in gene expression:
• p < 0.05 compared with NANOG; *p < 0.05 compared with OCT3/4; ◊p < 0.05 compared with CD34; †p < 0.05 compared with NESTIN; ‡p < 0.05 compared with SOX2. The higher the ΔCt, the lower the gene expression and vice versa.
gene expression. Figure 3 represents the above data.
Regarding the gene expression among CTCs and normal samples, it has been observed that in NANOG, OCT3/4 and CD34 the changes in gene expression are not quite different, while in NESTIN the gene expression is lower for CTCs. On the contrary, the SOX2 is overexpressed in CTCs. Figure 4 represents the above data. Finally, concerning the validation of CTCs prior to analysis, there were tested with both flow cytometry and PCR for expression of specific markers, depending on the cancer type. Table 1 presents these data.
Discussion
CTCs have been of interest to the scientific community for the last 15 years.
They have proved to be an invaluable resource for cancer prognosis because their existence has been shown in the majority of malignant tumors. Nevertheless, OCT3/4 is a transcription factor associated with pluripotency in embryonic stem cells. In particular, expression of OCT3/4 is required to maintain the pluripotent status of human embryonic stem cells by inhibiting expression of human chorionic gonadotropin, a placental marker of embryonic stem cells. Consequently, OCT3/4 is a stemness regulator in human embryonic stem cells [16] .
OCT3/4 appears to regulate dedifferentiation of melanoma cells [17] . It also plays an important role in gastric cancer progression and metastasis [18] . Expression of OCT3/4 protein has been found in lung adenocarcinoma stem cells, which correlates to poor clinical outcomes [19] . Moreover, OCT3/4 is detectable in other types of cancer, such as ovarian [20] [21], prostate [22] , and rectal [23] .
Various reviews [24] [25] have demonstrated that OCT3/4 is an upstream regulator of NANOG expression by binding to its promoter. When the levels of OCT3/4 are raised, it suppresses both its own expression and that of NANOG.
This negative feedback allows a cell to stably maintain NANOG levels. In addition, OCT3/4/SOX2 heterodimers induce expression of NANOG, which bind to its promoter and provoke its transcription. Downstream, potential targets of NANOG are cell cycle-related genes such as cyclin D1 that regulates the transition from G0 to G1 phase of the cell cycle [26] . Another study has suggested that, in embryonic stem cells, OCT3/4, SOX2, and NANOG bind to at least 353 genes in total and possibly influence their transcription. NANOG expression has been found in many types of cancer (breast, cervical, oral, kidney, prostate, lung, gastric, brain, and ovarian cancers), and its expression is associated with stemness properties [27] . Nevertheless, the exact role of NANOG in cancer is not es-tablished yet, because it does not appear to function as a simple oncogene [7] .
In addition to its role in NANOG regulation, SOX2 promotes cellular proliferation in various types of cancer, contributes to apoptosis inhibition, and enhances metastasis [28] .
The present study demonstrated that NANOG and OCT3/4 have similar expression profiles in CTCs of the majority of the different cancer types, but it is not always the case for the expression of both NANOG and OCT3/4 and SOX2.
In particular, colon, sarcoma, SCC, prostate, multiple myeloma, and ovarian cancers have similar expression of all three genes, whereas breast, melanoma, glioblastoma, and cancer of unknown origin have statistically different expression of OCT3/4 and SOX2 genes. These data suggest that the molecular me- CD34 is a transmembrane glycoprotein that was originally identified as a marker of hematopoietic stem cells. However, recent studies have suggested that CD34 is a marker of all progenitor cells, because its expression has been shown in multiple cell types [9] . This study revealed CD34 expression in CTCs from various cancer types. However, in most cases, its expression did not appear to be similar to that of any of the other stemness genes (NANOG, SOX2, OCT3/4, and NESTIN).
According to a previous study, CSCs are a subset of CTCs. CTCs have been found to express epithelial, mesenchymal or stemness markers [31] . CSC isolation is more difficult than CTC detection and isolation, which implies an inhibitory factor for cancer treatment. However, CTCs and CSCs exhibit common features including the expression of many genes. In breast cancer, CTCs have mesenchymal or stemness characteristics that can be used at a clinical level [32] . The present study indicates that some of the above mentioned stemness-associated genes might be important to maintain stemness or initiate metastasis. The present study should be performed in more samples from different kinds of cancer, since in some of them the number is not sufficient for global interpretation. However, these data are a useful indication for the majority of types.
Materials and Methods

Sample Collection
Blood samples from 71 patients were collected in sterile 50-ml falcon tubes (4440100; Orange Scientific) containing 7 ml of 0.02 M EDTA (E0511.0250; Duchefa Biochemie B.V.) as an anticoagulant. The cancer types of the samples included breast (24), colon (6), prostate (4), sarcoma (5), ovarian (2), melanoma (2), glioblastoma (2), multiple myeloma (3), SCC (4), and cancer with an unknown origin of the primary tumor (19) . The samples were collected randomly from physicians in U.S.A. and Europe. Regarding their age the average was 54.13 ± 3.77. Between them, the majority was female samples (68.9%), while the male samples were 31.4%. 65.2% of samples were received from U.S.A. and the rest 34.8% were collected from patients lived in European countries. The volume of collected blood was 20 mL. The samples were applied to a roller for 30 minutes and then sent to the laboratory for analysis. Transit of the samples to the laboratory did not exceed 72 h. The study was performed from January to June 2016. In addition, two normal samples were used as reference group for the qPCR analysis. The samples were collected from a healthy 40-year old man and a 32-year old woman.
Sample Stability
The period between transportation and analysis did not affect the experimental analysis. To ensure this, blood samples were collected from five healthy donors and placed in five different 50 ml falcon tubes. The tubes were then stored at 4˚C, which is the temperature of transportation package. Each day, starting from 0 h, every sample from each donor, was tested by using molecular and cellular assays. In a time window of 0, 24, 48, 72 and 96 h of storage, the gene expression of many genes correlated with cell cycle, apoptosis, cytoskeleton, stemness, cytokeratins, growth factors, signaling transduction pathways etc were tested. The same procedure was performed with flow cytometry to study the protein level.
Finally, the number of CTCs was measured for every sample each day. Ta data were analyzed and there was not observed any statistically significant difference among the different time periods. Concerning the above experimental data, the transit period, did not affect the analysis of the present study.
Sample Preparation
Whole 
Molecular Analysis
Total RNA from cell cultures was extracted using a MagCore Total RNA Cultured Cells Kit (MRC-02; RBC Bioscience). The samples were evaluated spectrophotometrically. Then, 1 µg of each RNA sample was used as a template for cDNA synthesis using a PrimeScript RT Reagent Kit (RR037A; Takara). Real-time qPCR was then performed using KAPA SYBR Fast Master Mix (2×) Universal (KK4618; KAPA Biosystems). Specific primers for each marker and the reference gene (ACTB) were designed using Gene Expression 1.1 software. Primer sequences were evaluated by BLAST searching to exclude those that would amplify undesired genes ( Table 2 ). The PCR program was as follows: initial denaturation at 95˚C for 3 min, 40 cycles of denaturation at 95˚C for 10 s followed by annealing at 59˚C for 30 s. Melting curve analysis was performed from 65˚C to 95˚C with 0.5˚C increments for 5 s at each step. The qPCR products were run on agarose gels to validate the results. ΔCt value was used for analysis of experiments. Finally, relative quantification was performed using the normal samples as the reference group according to Livak [35] . 
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Conclusion
We demonstrated that CTCs exhibit stemness characteristics and express specific transcription factors. Their expression is different and might be used to delineate either biomarkers or prognostic indicators. The higher expression of some genes may lead to the identification of potential drug targets. The genetic profiles among different types of cancer could also be used as a predictive reference in therapy. However, all the above aspects need to be tested in more samples including other types of cancer.
